Published in Lancet Oncol on March 26, 2012
Radiotherapy for Oligometastatic Prostate Cancer | NCT01859221
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. JAMA Oncol (2016) 1.62
Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials (2012) 1.48
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med (2017) 1.43
Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res (2013) 1.26
Increased chemosensitivity via targeting testicular nuclear receptor 4 (TR4)-Oct4-interleukin 1 receptor antagonist (IL1Ra) axis in prostate cancer CD133+ stem/progenitor cells to battle prostate cancer. J Biol Chem (2013) 0.97
The strategies to control prostate cancer by chemoprevention approaches. Mutat Res (2014) 0.87
Epidural analgesia during open radical prostatectomy does not improve long-term cancer-related outcome: a retrospective study in patients with advanced prostate cancer. PLoS One (2013) 0.85
Procyanidin B2 3,3(″)-di-O-gallate, a biologically active constituent of grape seed extract, induces apoptosis in human prostate cancer cells via targeting NF-κB, Stat3, and AP1 transcription factors. Nutr Cancer (2013) 0.82
Clinical evidence for the use of aspirin in the treatment of cancer. Ecancermedicalscience (2013) 0.81
LLW-3-6 and celecoxib impacts growth in prostate cancer cells and subcellular localization of COX-2. Anticancer Res (2014) 0.79
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis (2016) 0.79
Common medications and prostate cancer mortality: a review. World J Urol (2016) 0.77
Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer. Transl Androl Urol (2015) 0.77
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. J Clin Oncol (2017) 0.76
Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer. Invest New Drugs (2016) 0.76
Myxomaviral Anti-Inflammatory Serpin Reduces Myeloid-Derived Suppressor Cells and Human Pancreatic Cancer Cell Growth in Mice. J Cancer Sci Ther (2013) 0.75
Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai. Ecancermedicalscience (2016) 0.75
COX-2 inhibitors in prostate cancer treatment--hold your horses? Asian J Androl (2012) 0.75
Adaptive designs undertaken in clinical research: a review of registered clinical trials. Trials (2016) 0.75
Prostate cancer: celecoxib trampled in the STAMPEDE trial. Nat Rev Urol (2012) 0.75
The STAMPEDE trial and celecoxib: how to adapt? Lancet Oncol (2012) 0.75
Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS). PLoS One (2017) 0.75
Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis. Oncogene (2017) 0.75
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (2010) 19.74
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med (2005) 12.46
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology (1994) 8.79
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med (2000) 7.54
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet (2008) 7.14
Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet (2011) 5.76
COX-2 inhibitors. Lancet (1999) 5.49
Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res (2000) 4.18
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol (2007) 3.51
Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst (2010) 2.80
Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. J Clin Oncol (2010) 2.32
Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol (2006) 2.29
Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst (1998) 2.26
Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer. Stat Med (2003) 2.21
Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst (1998) 2.09
Speeding up the evaluation of new agents in cancer. J Natl Cancer Inst (2008) 2.08
A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc (2002) 2.04
New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res (2011) 2.01
The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med (2011) 1.92
Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. Trials (2009) 1.81
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71
Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol (1993) 1.53
An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer (2010) 1.32
Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit. Trials (2011) 1.30
Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep (2000) 1.25
Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J Urol (2004) 1.08
Improving outcomes with recent advances in chemotherapy for castrate-resistant prostate cancer. Clin Genitourin Cancer (2010) 0.86
Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies. Expert Rev Anticancer Ther (2010) 0.83
Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet (2008) 15.43
Practical methods for incorporating summary time-to-event data into meta-analysis. Trials (2007) 14.51
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med (2004) 10.41
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med (2012) 8.64
A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med (2011) 8.63
Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med (2002) 6.10
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet (2009) 6.04
International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol (2011) 5.95
Multiple loci with different cancer specificities within the 8q24 gene desert. J Natl Cancer Inst (2008) 5.82
Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet (2011) 5.76
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol (2007) 5.00
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet (2007) 4.68
Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet (2009) 3.94
Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care (2013) 3.89
Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09). Lancet Oncol (2013) 3.85
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet (2010) 3.78
Antegrade perfusion with bacillus Calmette-Guérin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit? Eur Urol (2011) 3.47
Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer (2009) 3.31
The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol (2007) 3.20
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer (2007) 3.15
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet (2011) 3.07
Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res (2007) 3.07
Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncol (2011) 3.04
Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst (2007) 2.86
Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst (2007) 2.85
Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. J Urol (2008) 2.83
Twenty years experience with an ileal orthotopic low pressure bladder substitute--lessons to be learned. J Urol (2006) 2.82
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet (2008) 2.77
A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst (2003) 2.68
Nerve sparing open radical retropubic prostatectomy--does it have an impact on urinary continence? J Urol (2006) 2.65
High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol (2003) 2.65
Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci Transl Med (2012) 2.64
Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res (2010) 2.62
Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol (2008) 2.57
Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet (2002) 2.57
A new multimodality technique accurately maps the primary lymphatic landing sites of the bladder. Eur Urol (2009) 2.55
Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol (2008) 2.53
Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol (2008) 2.46
High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res (2010) 2.39
Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy. J Clin Oncol (2003) 2.33
Is pelvic lymph node dissection necessary in patients with a serum PSA<10ng/ml undergoing radical prostatectomy for prostate cancer? Eur Urol (2006) 2.32
Secondhand smoke in apartment buildings: renter and owner or manager perspectives. Nicotine Tob Res (2007) 2.31
A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol (2012) 2.31
The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria. Cancer (2011) 2.29
Visualizing length of survival in time-to-event studies: a complement to Kaplan-Meier plots. J Natl Cancer Inst (2008) 2.26
Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol (2008) 2.25
Restrictive deferred hydration combined with preemptive norepinephrine infusion during radical cystectomy reduces postoperative complications and hospitalization time: a randomized clinical trial. Anesthesiology (2014) 2.25
A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. Eur Urol (2008) 2.25
Induction of heat shock proteins in B-cell exosomes. J Cell Sci (2005) 2.21
Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer. Stat Med (2003) 2.21
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
Human cytomegalovirus escapes a naturally occurring neutralizing antibody by incorporating it into assembling virions. Cell Host Microbe (2011) 2.20
The role of surgery in high-risk localised prostate cancer. BJU Int (2011) 2.19
Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol (2009) 2.18
Evaluating the efficacy of statins and ACE-inhibitors in reducing gastrointestinal toxicity in patients receiving radiotherapy for pelvic malignancies. Eur J Cancer (2012) 2.17
Medium-term outcomes of active surveillance for localised prostate cancer. Eur Urol (2013) 2.16
Can urinary exosomes act as treatment response markers in prostate cancer? J Transl Med (2009) 2.14
Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. J Urol (2011) 2.14
Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res (2002) 2.09
A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol (2012) 2.09
Proteomics analysis of bladder cancer exosomes. Mol Cell Proteomics (2010) 2.04
Occlusion of seminal vesicles increases sexual activity in a mouse model. Eur Urol (2012) 2.03
An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer. Eur J Cancer (2012) 1.97
Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol (2005) 1.95
The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med (2011) 1.92
Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J Immunol (2011) 1.90
Using implicit information to identify smoking status in smoke-blind medical discharge summaries. J Am Med Inform Assoc (2007) 1.89
Systematic qualitative review of the literature on data monitoring committees for randomized controlled trials. Clin Trials (2004) 1.85
Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol (2005) 1.83
Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. Trials (2009) 1.81
The clinical management of patients with a small volume of prostatic cancer on biopsy: what are the risks of progression? A systematic review and meta-analysis. Cancer (2008) 1.79
Late recurrence in 1263 men with testicular germ cell tumors. Multivariate analysis of risk factors and implications for management. Cancer (2002) 1.79
Early prostate cancer--which treatment do men prefer and why? BJU Int (2010) 1.79
Adhesion and signaling by B cell-derived exosomes: the role of integrins. FASEB J (2004) 1.77
Stereotactic body radiotherapy for oligometastases. Lancet Oncol (2013) 1.76
Effects of dexmedetomidine on propofol and remifentanil infusion rates during total intravenous anesthesia for spine surgery in adolescents. Paediatr Anaesth (2008) 1.74
Cell-specific radiosensitization by gold nanoparticles at megavoltage radiation energies. Int J Radiat Oncol Biol Phys (2010) 1.72